Artificial intelligence in ovarian cancer: advancing in precision diagnosis and clinical management - Top-Institutions - MDSpire

Artificial intelligence in ovarian cancer: advancing in precision diagnosis and clinical management

  • By

  • Mingjun Shao

  • Tong Wang

  • Limei Ji

  • Lili Xu

  • Yanfei Zhang

  • Dongge Wang

  • Cenlin Jia

  • Lin Chen

  • Heng Zhang

  • Wei Yan

  • Xuehao Cui

  • Ran Tong

  • May 7, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Cancer Research

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Cancer Research

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, Massachusetts

    Key Differentiators

    • Oncology
    • Cancer Research

  • #4

    University of California San Diego Moores Cancer Center
    University of California San Diego Moores Cancer Center

    La Jolla, California

    Key Differentiators

    • Oncology
    • Cancer Research

  • #5

    Bumrungrad International Hospital
    Bumrungrad International Hospital

    Bangkok, Thailand

    Key Differentiators

    • Oncology
    • General Healthcare

Original Source(s)

Artificial intelligence in ovarian cancer: advancing in precision diagnosis and clinical management

  • by Mingjun Shao, Tong Wang, Limei Ji, Lili Xu, Yanfei Zhang, Dongge Wang, Cenlin Jia, Lin Chen, Heng Zhang, Wei Yan, Xuehao Cui, Ran Tong

  • May 7, 2026

Related Content

One Pathway for Esophageal Cancer?

Molecular profiling reveals precursor signals in BE-negative esophageal cancer

  • May 7, 2026

  • 2 min
Plasma miR-371a-3p Predicts Recurrence in Stage I Testicular Cancer: Interim Results From the CLIMATE Study

In the management of stage I testicular cancer, a persistent clinical dilemma is the identification of patients who truly need adjuvant treatment after orchiectomy rather than active surveillance alon...

‘Promising’ Signal Only: ctDNA in Early Breast Cancer Not Yet Ready for Clinical Use

Despite compelling prognostic associations across multiple retrospective data sets, no interventional trial has demonstrated that acting on circulating tumor DNA testing results in early breast cancer...